XML 69 R8.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
3 Months Ended
Mar. 28, 2020
Mar. 30, 2019
Cash Flows From (For) Operating Activities    
Net income $ 106.4 $ 63.9
Adjustments to derive cash flows:    
Depreciation and amortization 93.1 96.6
Share-based compensation 16.2 12.4
Impairment charges 0.0 4.1
Change in financial assets (1.6) (10.4)
Restructuring charges 0.0 9.3
Deferred income taxes 6.7 3.9
Amortization of debt premium (0.7) (1.9)
Other non-cash adjustments, net (14.0) 13.4
Subtotal 206.1 191.3
Increase (decrease) in cash due to:    
Accounts receivable (67.6) (48.5)
Inventories 36.5 (37.5)
Prepaid expenses (33.4) (3.7)
Accounts payable 53.8 75.4
Payroll and related taxes (18.4) (19.9)
Accrued customer programs (13.6) (61.7)
Accrued liabilities 11.1 (3.8)
Accrued income taxes 3.8 (10.0)
Other, net (6.5) 12.9
Subtotal (34.3) (96.8)
Net cash from operating activities 171.8 94.5
Cash Flows From (For) Investing Activities    
Proceeds from royalty rights 1.8 1.2
Acquisitions of businesses, net of cash acquired (11.3) 0.0
Proceeds from the Royalty Pharma contingent milestone 0.0 250.0
Asset acquisitions (32.7) 0.0
Additions to property, plant and equipment (33.8) (21.1)
Other investing, net 1.2 0.0
Net cash from (for) investing activities (74.8) 230.1
Cash Flows From (For) Financing Activities    
Payments on long-term debt 0.0 (12.3)
Borrowings (repayments) of revolving credit agreements and other financing, net 102.0 (0.3)
Cash dividends (30.9) (25.9)
Other financing, net (6.4) (3.1)
Net cash from (for) financing activities 64.7 (41.6)
Effect of exchange rate changes on cash and cash equivalents (5.6) 3.8
Net increase (decrease) in cash and cash equivalents 156.1 286.8
Cash and cash equivalents, beginning of period 354.3 551.1
Cash and cash equivalents, end of period $ 510.4 $ 837.9